CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

NCT04214886 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Acute Lymphoblastic Leukemia, Adult
B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: CD19-CD34 CAR transduced T cells

Sponsor

Loyola University

Collaborators

[object Object]